BIOLOGICAL TESTING FACILITY - CONTRACEPTIVE TARGET APPLICATION

生物测试设施 - 避孕目标应用

• 批准号: 10576708
• 负责人: DEBORAH BUNIN
• 金额: $ 22.9万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-17 至 2022-11-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10576708
• 关键词: Area; Bioinformatics; Biological Testing; Clinical; Clinical Trials; Collaborations; Contraceptive Agents; Contraceptive Availability; Contraceptive Devices; Data; Databases; Development; Devices; Drug Formulations; Evaluation; In Vitro; Internet; Investigational New Drug Application; Knowledge; Maintenance; Pharmaceutical Preparations; Phase; Preparation; Process; Research Personnel; Safety; System; Toxicology; Update; Work; contraceptive target; design; drug discovery; drug testing; efficacy evaluation; in vivo; next generation; novel; novel strategies; pre-clinical; reproductive; stability testing; user-friendly; web app; web site

Early phase non-steroidal contraceptive discovery and development is limited by known targets and readily accessibility of this information. It is important to facilitate the discovery, curation and availability of contraceptive targets with the aim of developing new approaches to advance next generation of safe contraceptive drug/device. To alleviate this obstacle, bioinformatics driven approach to identify and curate those targets from the existing databases was established. To further allow easy accessibility and friendly user interface for this database, a web application is needed. The Biological Testing Facility has bioinformatics and web design and application capability to achieve this task, in addition to permit rapid evaluation (in vitro and in vivo) of new compositions of matter to the target, efficacy evaluation, safety/ toxicology assessment, drug formulations, delivery systems, and devices for contraceptives followed by clinical batch preparation/ release and continued stability testing of drugs to be evaluated in clinical trials. The BTF provides overall project management and the capabilities to support all phases of novel target product identification, drug discovery/ optimization, preclinical activities and development of contraceptives and associated tasks leading to the filing of investigational new drug (IND) applications.

早期非甾体避孕发现和开发受已知目标的限制 并随时可访问此信息。促进发现，策展很重要 以及避孕目标的可用性，目的是开发新的方法来进步 下一代安全的避孕药/设备。为了减轻这一障碍，生物信息学驱动 从现有数据库中识别和策划这些目标的方法。到 进一步允许此数据库的易于访问性和友好的用户界面，Web应用程序是 需要。生物测试设施具有生物信息学，网页设计和应用 除了允许对新的快速评估（体外和体内）外，还可以实现这一任务 物质向目标的组成，疗效评估，安全/毒理学评估，药物 避孕药的配方，输送系统和设备，然后是临床批次 在临床试验中评估的药物的制备/释放和持续稳定性测试。这 BTF提供了整体项目管理和支持新目标的所有阶段的能力 产品识别，药物发现/优化，临床前活动和开发 避孕药和相关任务，导致提交研究新药（IND） 申请。